Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, ...
Justin C. Frankel, P.C., represented a client with Chronic Lymphocytic Leukemia whose long-term disability benefits ...
​Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Robert ...
After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.
Better treatment and earlier diagnosis mean that 7 in 10 people will survive five years or more after a cancer diagnosis.
Oncoscope launches the first Real-time, AI-supported Living Systematic Literature Review designed for enterprise-wide ...
In November 2025, Nurix appointed accomplished biopharmaceutical leader Roger Dansey, M.D., to its Board of Directors, adding ...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.5, with a high ...
Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
Researchers analyzed the health records of more than 33,800 U.S. veterans diagnosed with non-melanoma skin cancer and found ...
Artificial Intelligence has been the catalyst behind the blockbuster rally in equity markets over the past two years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results